PTGS1 and preeclampsia: Selective inhibition of COX-1 which targets thromboxane A2, is known to occur at doses < 300 mg, but a debate exists in the literature about the appropriate aspirin dose to mitigate preeclampsia risk [17,29,30] and the role of aspirin resistance [13,14].